trial · primary record
Daratumumab Injection
Plasma Cell Disorder
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2032-10-01 |
| Primary endpoint | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] |
| Registry ID | NCT07075510 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:13.442Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07075510
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.